NCT03448237 (Pro-Pho-Dys) is a NA clinical trial of Speech Therapy in Developmental Dyslexia, sponsored by Scalab CNRS 9193.

Who is sponsoring NCT03448237?

NCT03448237 is sponsored by Scalab CNRS 9193.

What drugs are being tested in NCT03448237?

Interventions in NCT03448237: Speech Therapy, Proprioceptive treatment.

What condition does NCT03448237 study?

NCT03448237 studies Developmental Dyslexia.

Is NCT03448237 still recruiting?

NCT03448237 is currently status unknown. Last updated 17 March 2020.

Last reviewed 2020-03-17 · How we verify

NCT03448237: Pro-Pho-Dys

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Orthophonic and / or Proprioceptive Treatment of Developmental Dyslexia.

Status unknown NA Last updated 17 March 2020

What this trial tests

NA trial testing Speech Therapy in Developmental Dyslexia in 26 participants. Status unknown.

Timeline

17 February 2018

Primary endpoint
5 October 2019

10 October 2020

Quick facts

Lead sponsor	Scalab CNRS 9193
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	26
Start date	17 February 2018
Primary completion	5 October 2019
Estimated completion	10 October 2020
Sites	1 location across France

Drugs / interventions tested

Speech Therapy
Proprioceptive treatment

Conditions studied

Developmental Dyslexia — all drugs for Developmental Dyslexia →

Sponsor

Scalab CNRS 9193

Who can join

Adults 9 to 14, any sex, with Developmental Dyslexia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To show the interest of the association of proprioceptive and orthophonic care of dyslexic children. The assumption is that proprioceptive support by correcting a centrally located spatial localization instability restores the ability to automate. It allows a gain of effectiveness of the orthophonic remediation of the reading of dyslexic children. Interventional comparative study over 9 months, of three modes of care: Speech-language, or proprioceptive, or combined (speech therapy or proprioceptive)

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Speech Therapy

Trials testing the same drug.

NCT06010030 — HD-tDCS for Phonological Impairment in Aphasia · NA · active not recruiting
NCT05900180 — Pediatric Speech Therapy Session Frequency and Speech Outcomes · NA · active not recruiting
NCT05306782 — Shaping Motor Neural Functioning of Developmental Stuttering to Improve Fluency · NA · completed
NCT05187910 — Correlation Between Montreal Cognitive Assessment and Voice Therapy Outcomes in the Aging Treatment- Seeking Population · NA · completed

Other recruiting trials for Developmental Dyslexia

Currently open trials in the same condition.

NCT05972200 — V5/MT Stimulation on Reading and Reading-related Measures in Developmental Dyslexia · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03448237 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Scalab CNRS 9193
Last refreshed: 17 March 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03448237.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing